1887

Journal of General Virology header logo

Volume 88, Issue 1

A recombinant non-pathogenic vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection Free

Abstract

Live-vector human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation that have yielded promising results in pre-clinical testing. In this report, a non-pathogenic protozoan parasitic vector, , which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein. Immunization of BALB/c mice with recombinant led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8 T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant elicited effector memory HIV-1 Gag-specific CD4 T lymphocytes and increased antibody titres against HIV-1 Gag. Most importantly, immunization of human tonsillar tissue cultured with Gag-expressing vaccine vector elicited a 75 % decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection. These results demonstrated that recombinant is capable of eliciting effective immune responses in mice and human systems, respectively, and suggest that this novel non-pathogenic recombinant vaccine vector shows excellent promise as a vaccination strategy against HIV-1.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81995-0
2007-01-01
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/217.html?itemId=/content/journal/jgv/10.1099/vir.0.81995-0&mimeType=html&fmt=ahah

References

  1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. 1986; Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284–291
     [Google Scholar]
  2. Amara R. R., Villinger F., Altman J. D., Lydy S. L., O'Neil S. P., Staprans S. I., Montefiori D. C., Xu Y., Herndon J. G. other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74 [CrossRef]
     [Google Scholar]
  3. Andersson E. C., Christensen J. P., Marker O., Thomsen A. R. 1994; Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. J Immunol 152:1237–1245
     [Google Scholar]
  4. Baba T. W., Jeong Y. S., Pennick D., Bronson R., Greene M. F., Ruprecht R. M. 1995; Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820–1825 [CrossRef]
     [Google Scholar]
  5. Barouch D. H., Santra S., Kuroda M. J., Schmitz J. E., Plishka R., Buckler-White A., Gaitan A. E., Zin R., Nam J.-H. other authors 2001; Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75:5151–5158 [CrossRef]
     [Google Scholar]
  6. Barouch D. H., McKay P. F., Sumida S. M., Santra S., Jackson S. S., Gorgone D. A., Lifton M. A., Chakrabarti B. K., Xu L. other authors 2003; Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77:8729–8735 [CrossRef]
     [Google Scholar]
  7. Betts M. R., Ambrozak D. R., Douek D. C., Bonhoeffer S., Brenchley J. M., Casazza J. P., Koup R. A., Picker L. J. 2001; Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75:11983–11991 [CrossRef]
     [Google Scholar]
  8. Bounou S., Leclerc J. E., Tremblay M. J. 2002; Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4+-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76:1004–1014 [CrossRef]
     [Google Scholar]
  9. Breton M., Tremblay M. J., Ouellette M., Papadopoulou B. 2005; Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73:6372–6382 [CrossRef]
     [Google Scholar]
  10. Brun R., Schönenberger M. 1979; Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop 36:289–292
     [Google Scholar]
  11. Clayton C. E. 2002; Life without transcriptional control? From fly to man and back again. EMBO J 21:1881–1888 [CrossRef]
     [Google Scholar]
  12. DeGrendele H. C., Estess P., Siegelman M. H. 1997; Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278:672–675 [CrossRef]
     [Google Scholar]
  13. Donnelly J. J., Wahren B., Liu M. A. 2005; DNA vaccines: progress and challenges. J Immunol 175:633–639 [CrossRef]
     [Google Scholar]
  14. Gilbert P. B., Peterson M. L., Follmann D., Hudgens M. G., Francis D. P., Gurwith M., Heyward W. L., Jobes D. V., Popovic V. other authors 2005; Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191:666–677 [CrossRef]
     [Google Scholar]
  15. Glushakova S., Baibakov B., Margolis L. B., Zimmerberg J. 1995; Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med 1:1320–1322 [CrossRef]
     [Google Scholar]
  16. Goulder P. J. R., Altfeld M. A., Rosenberg E. S., Nguyen T., Tang Y., Eldridge R. L., Addo M. M., He S., Mukherjee J. S. other authors 2001; Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193:181–194 [CrossRef]
     [Google Scholar]
  17. Granucci F., Feau S., Zanoni I., Pavelka N., Vizzardelli C., Raimondi G., Ricciardi-Castagnoli P. 2003; The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis 187 (Suppl. 2):S346–S350 [CrossRef]
     [Google Scholar]
  18. Grivel J.-C., Biancotto A., Ito Y., Lima R. G., Margolis L. B. 2003; Bystander CD4+ T lymphocytes survive in HIV-infected human lymphoid tissue. AIDS Res Hum Retroviruses 19:211–216 [CrossRef]
     [Google Scholar]
  19. Harrer T., Harrer E., Kalams S. A., Elbeik T., Staprans S. I., Feinberg M. B., Cao Y., Ho D. D., Yilma T. other authors 1996; Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12:585–592 [CrossRef]
     [Google Scholar]
  20. Horton H., Vogel T. U., Carter D. K., Vielhuber K., Fuller D. H., Shipley T., Fuller J. T., Kunstman K. J., Sutter G. other authors 2002; Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 76:7187–7202 [CrossRef]
     [Google Scholar]
  21. Janssen E. M., Lemmens E. E., Wolfe T., Christen U., von Herrath M. G., Schoenberger S. P. 2003; CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852–856 [CrossRef]
     [Google Scholar]
  22. Jin X., Bauer D. E., Tuttleton S. E., Lewin S., Gettie A., Blanchard J., Irwin C. E., Safrit J. T., Mittler J. other authors 1999; Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991–998 [CrossRef]
     [Google Scholar]
  23. Klenerman P., Hill A. 2005; T cells and viral persistence: lessons from diverse infections. Nat Immunol 6:873–879 [CrossRef]
     [Google Scholar]
  24. Letvin N. L. 2005; Progress toward an HIV vaccine. Annu Rev Med 56:213–223 [CrossRef]
     [Google Scholar]
  25. Letvin N. L., Barouch D. H., Montefiori D. C. 2002; Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20:73–99 [CrossRef]
     [Google Scholar]
  26. MacGregor R. R., Boyer J. D., Ugen K. E., Lacy K. E., Gluckman S. J., Bagarazzi M. L., Chattergoon M. A., Baine Y., Higgins T. J. other authors 1998; First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92–100 [CrossRef]
     [Google Scholar]
  27. Margolis L. B., Fitzgerald W., Glushakova S., Hatfill S., Amichay N., Baibakov B., Zimmerberg J. 1997; Lymphocyte trafficking and HIV infection of human lymphoid tissue in a rotating wall vessel bioreactor. AIDS Res Hum Retroviruses 13:1411–1420 [CrossRef]
     [Google Scholar]
  28. Mashishi T., Gray C. M. 2002; The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 40:903–910
     [Google Scholar]
  29. McConkey S. J., Reece W. H. H., Moorthy V. S., Webster D., Dunachie S., Butcher G., Vuola J. M., Blanchard T. J., Gothard P. other authors 2003; Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729–735 [CrossRef]
     [Google Scholar]
  30. McMichael A. J., Hanke T. 2003; HIV vaccines 1983–2003. Nat Med 9:874–880 [CrossRef]
     [Google Scholar]
  31. Melief C. J. M. 2003; Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Immunol 33:2645–2654 [CrossRef]
     [Google Scholar]
  32. Moore J. P., Trkola A., Korber B., Boots L. J., Kessler J. A. II, McCutchan F. E., Mascola J., Ho D. D., Robinson J., Conley A. J. 1995; A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 69:122–130
     [Google Scholar]
  33. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y. other authors 1989; A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246:1293–1297 [CrossRef]
     [Google Scholar]
  34. Norton J. D. 1997; Technical tips online. Simple and efficient panning of transfected cell populations expressing a cell surface marker. Trends Genet 13:41 [CrossRef]
     [Google Scholar]
  35. Papadopoulou B., Roy G., Ouellette M. 1992; A novel antifolate resistance gene on the amplified H circle of Leishmania . EMBO J 11:3601–3608
     [Google Scholar]
  36. Redfield R. R., Wright D. C., James W. D., Jones T. S., Brown C., Burke D. S. 1987; Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673–676 [CrossRef]
     [Google Scholar]
  37. Schmitz J. E., Kuroda M. J., Santra S., Sasseville V. G., Simon M. A., Lifton M. A., Racz P., Tenner-Racz K., Dalesandro M. other authors 1999; Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857–860 [CrossRef]
     [Google Scholar]
  38. Seaman M. S., Peyerl F. W., Jackson S. S., Lifton M. A., Gorgone D. A., Schmitz J. E., Letvin N. L. 2004; Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 78:206–215 [CrossRef]
     [Google Scholar]
  39. Seth A., Ourmanov I., Schmitz J. E., Kuroda M. J., Lifton M. A., Nickerson C. E., Wyatt L., Carroll M., Moss B. other authors 2000; Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74:2502–2509 [CrossRef]
     [Google Scholar]
  40. Shedlock D. J., Shen H. 2003; Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337–339 [CrossRef]
     [Google Scholar]
  41. Whitney J. B., Ruprecht R. M. 2004; Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17:17–26 [CrossRef]
     [Google Scholar]
  42. Yan S., Lodes M. J., Fox M., Myler P. J., Stuart K. 1999; Characterization of the Leishmania donovani ribosomal RNA promoter. Mol Biochem Parasitol 103:197–210 [CrossRef]
     [Google Scholar]
  43. Zhao C., Papadopoulou B., Tremblay M. J. 2004; Leishmania infantum promotes replication of HIV type 1 in human lymphoid tissue cultured ex vivo by inducing secretion of the proinflammatory cytokines TNF- α and IL-1 α . J Immunol 172:3086–3093 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81995-0
Loading
A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection
J. Gen. Virol. 88, 217 (2007); https://doi.org/10.1099/vir.0.81995-0
/content/journal/jgv/10.1099/vir.0.81995-0
/content/journal/jgv/10.1099/vir.0.81995-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error